BR112016007031A8 - composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida - Google Patents

composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida Download PDF

Info

Publication number
BR112016007031A8
BR112016007031A8 BR112016007031A BR112016007031A BR112016007031A8 BR 112016007031 A8 BR112016007031 A8 BR 112016007031A8 BR 112016007031 A BR112016007031 A BR 112016007031A BR 112016007031 A BR112016007031 A BR 112016007031A BR 112016007031 A8 BR112016007031 A8 BR 112016007031A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
solid oral
oral pharmaceutical
preparing
solid
Prior art date
Application number
BR112016007031A
Other languages
English (en)
Other versions
BR112016007031A2 (pt
Inventor
Sehgal Ashish
Singh Balvir
Patel Mahendra
Patel Mayur
Patel Priyank
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of BR112016007031A2 publication Critical patent/BR112016007031A2/pt
Publication of BR112016007031A8 publication Critical patent/BR112016007031A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se relaciona com composições farmacêuticas compreendendo combinações de dose fixa de capecitabina e ciclofosfamida, processos para a sua preparação e a sua utilização para tratar doenças oncológicas.
BR112016007031A 2013-09-30 2014-09-29 composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida BR112016007031A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3118MU2013 IN2013MU03118A (pt) 2013-09-30 2014-09-29
PCT/IN2014/000625 WO2015044961A2 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide

Publications (2)

Publication Number Publication Date
BR112016007031A2 BR112016007031A2 (pt) 2017-08-01
BR112016007031A8 true BR112016007031A8 (pt) 2020-02-27

Family

ID=52744637

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007031A BR112016007031A8 (pt) 2013-09-30 2014-09-29 composição farmacêutica oral sólida, processo para preparar a composição farmacêutica oral sólida, e uso de uma composição farcêutica oral sólida

Country Status (9)

Country Link
US (1) US20160243034A1 (pt)
EP (1) EP3052130B1 (pt)
AU (1) AU2014326142B2 (pt)
BR (1) BR112016007031A8 (pt)
CA (1) CA2925960A1 (pt)
ES (1) ES2753435T3 (pt)
IN (1) IN2013MU03118A (pt)
MX (1) MX2016004094A (pt)
WO (1) WO2015044961A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613563A (en) * 2014-06-12 2016-04-16 Sanofi Synthelabo India Ltd Bi-layer tablet formulations of cyclophosphamide and CAPECITABINE and highly fractionated METRONOMIC administration thereof
EP3197438A4 (en) * 2014-09-26 2018-06-20 Intas Pharmaceuticals Ltd. Pharmaceutical composition having improved content uniformity
US20190142755A1 (en) * 2016-05-03 2019-05-16 Intas Pharmaceuticals Ltd. Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US20090311249A1 (en) * 2006-06-02 2009-12-17 Luca Gianni Capecitabine Combination Therapy
AU2010250800A1 (en) * 2009-05-20 2012-01-12 Ranbaxy Laboratories Limited Oral compositions of celecoxib
EP2747571A4 (en) * 2011-08-24 2015-05-27 David Kerr COMBINED COMBINED CHEMOTHERAPY
CN103251569B (zh) * 2013-05-30 2015-10-28 成都苑东药业有限公司 卡培他滨片组合物及其制备方法

Also Published As

Publication number Publication date
CA2925960A1 (en) 2015-04-02
WO2015044961A3 (en) 2015-06-04
AU2014326142A1 (en) 2016-04-21
US20160243034A1 (en) 2016-08-25
MX2016004094A (es) 2016-10-28
BR112016007031A2 (pt) 2017-08-01
WO2015044961A2 (en) 2015-04-02
EP3052130B1 (en) 2019-08-07
ES2753435T3 (es) 2020-04-08
EP3052130A4 (en) 2017-05-31
IN2013MU03118A (pt) 2015-08-14
EP3052130A2 (en) 2016-08-10
AU2014326142B2 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691582A1 (ru) Новые фармацевтические препараты
PH12016500094A1 (en) Autotaxin inhibitors
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
GT201400111A (es) Triazolopiridinas sustituidas
BR112019024747A2 (pt) formulações de dose fixa
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
DOP2016000253A (es) Nuevos compuestos
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
BR112015031417A8 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
EA201501175A1 (ru) Новые соединения для лечения злокачественного новообразования
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2599 DE 27-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.